|Bid||41.64 x 1100|
|Ask||41.69 x 900|
|Day's Range||41.15 - 41.83|
|52 Week Range||33.80 - 69.43|
|Beta (3Y Monthly)||2.34|
|PE Ratio (TTM)||17.82|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.20|
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
Cambrex Corp NYSE:CBMView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for CBM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CBM had net inflows of $1.86 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Basic Materials sector is rising. The rate of growth is weak relative to the trend shown over the past year, but is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Cambrex (CBM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cambrex (CBM) delivered earnings and revenue surprises of 17.65% and -0.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The East Rutherford, New Jersey-based company said it had net income of 31 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, came to 60 cents per share. The results ...
- Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Reaffirms full year financial guidance - - Conference.
EAST RUTHERFORD, N.J., April 30, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services.
Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had opened a new 120m2 quality control (QC) laboratory at its site in Paullo, Milan, Italy. The laboratory expands on the current QC facilities that analyze and test its generic API portfolio of products during development and manufacturing. The QC laboratory is now fully operational, having been authorized by the Agenzia Italiana Del Farmaco (AIFA).
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. For example, long term Ca...
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA. The production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m3 and contain 4 reactors ranging from 200 to 1,000 gallon capacity enabling manufacturing campaigns of batch sizes up to 300 kg. With the completion of this new facility, the Charles City site now has the flexibility to support all phases of development and offer all scales of HPAPI manufacture across the full OEL band spectrum.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
EAST RUTHERFORD, N.J., March 26, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services.
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m2 research and development laboratory at its site in Paullo, Milan, Italy. In addition, Cambrex has installed a new 12,000 liter reactor into one of its cGMP manufacturing facilities at the site. The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems, which have now been qualified and validated.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll look at Cambrex Corporation's (NYSE:CBM) P/E ratio and reflect onRead More...
To receive further updates on this Cambrex Corporation (NYSE:CBM) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of Power Options Weekly today.This morning I'm recommending a bearish trade on Cambrex Corporation (NYSE:CBM), a life sciences company.While my indicators are giving bullish readings again this week, they dipped briefly into neutral territory this week as the S&P 500 struggled to clear its 200-day moving average. The rally from the late-December bottom remains intact, although we did get some economic news on Thursday that was somewhat concerning.InvestorPlace - Stock Market News, Stock Advice & Trading TipsRetail sales dropped a seasonally adjusted 1.2% in December, which was the largest monthly drop since 2009. December is typically one of the stronger months for retail sales, as a lot of consumers do their holiday shopping that month, so this reading came as a surprise to Wall Street.Though I remain bullish in the near term, I am recommending a defensive position this morning in case the market makes a move to the downside. CBM missed earnings this week, and it has exposure in Europe, so I decided it would be a good downside play. Europe is StrugglingThe economic situation in Europe is not good at all. Their central bankers are all out of options for stimulating the region's economies, and that weakness has the potential to creep over into our markets eventually.Two of the three subsidiaries that own CBM's manufacturing facilities are located in Europe. CBM also has research and development facilities throughout Europe. If we do start to see Europe's economic issues affect our market, it will start with companies like CBM. No Support Above $30CBM reported earnings on Feb. 13, before market open, and it missed earnings estimates by over 90%. The stock dropped below support at the $36 level, and yesterday it dropped even further.Daily Chart of Cambrex Corporation (CBM) -- Chart Source: TradingViewCBM set a new 52-week low this week, and its next support level -- from early 2017 -- is at $30. The fundamental picture looks bad, and CBM doesn't have the technical support to keep the stock from falling further. That's why I'm recommending a bearish play this morning.Buy to open the Cambrex Corporation (CBM) April 18th $30 Puts (CBM190418P00030000) at $0.75 or lower. Note: The Good Friday holiday falls on April 19th, 2019. Because U.S. markets will be closed that day, April monthly options will expire the day before, on April 18th, 2019.Follow our Facebook page to receive each Trade of the Day direct to your News Feed -- and join the conversation.InvestorPlace advisor Ken Trester brings you Power Options Weekly, which delivers 5 new options trades and his latest trading advice to you each Friday. Trester has been trading options since the first exchanges opened in 1973 with a winning streak that goes back to 1984 with money-doubling average annual profits since 1990.Compare Brokers The post CBM Missed Earnings by Over 90% appeared first on InvestorPlace.